Healthcare Global Enterprises Ltd (HCG) Q1 FY27 Results Analysis: Revenue Growth Misses 15% Target, EBITDA Margin Expansion Minimal
Healthcare Global Enterprises Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 693.39 Cr (+13.34% YoY) and PAT growth of +189.89% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 693.39 Cr (+13.34% YoY) |
| PAT (Q1) | Rs. 13.77 Cr (+189.89% YoY) |
| EBITDA margin | 17.77% (+4 bps YoY) |
| EPS (Q1) | Rs. 0.92 (+170.59% YoY) |
| Market cap | Rs. 10,130.15 Cr |
| CMP | Rs. 678.50 |
Quarter Snapshot
Consolidated revenue growth of 13.34% missed the 15%+ guidance, while standalone growth met the target. EBITDA margin expansion was minimal, raising concerns about achieving the annual 100 bps target. Strong PAT growth was partly driven by one-time gains and lower finance costs.
Key Investment Insights
Key Positives
- Standalone revenue grew 15.13% YoY, meeting the 15%+ guidance
- PAT-owners grew 189.89% YoY to Rs.13.77 Cr
- Finance costs declined 12.32% YoY, reflecting deleveraging
- Normalized PAT-owners (excluding one-time gain) grew 148.8% YoY
- Subsidiary contribution to PAT-owners increased to 59.5% from 27.4% YoY
Risk Factors
- Consolidated revenue growth of 13.34% YoY missed the 15%+ guidance
- EBITDA margin expanded only 4 bps YoY, below the 100 bps annual target
- Medical consultancy charges grew 18.38% YoY, outpacing revenue by ~500 bps
- Other expenses grew 17.16% YoY, also outpacing revenue
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.